Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Kymera Therapeutics (KYMR) Financials

Kymera Therapeutics logo
$78.14 -1.53 (-1.92%)
Closing price 04:00 PM Eastern
Extended Trading
$78.16 +0.02 (+0.02%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Kymera Therapeutics

Annual Income Statements for Kymera Therapeutics

This table shows Kymera Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -41 -55 -100 -155 -147 -224 -311
Consolidated Net Income / (Loss)		 -41 -46 -100 -155 -147 -224 -311
Net Income / (Loss) Continuing Operations		 -40 -46 -100 -155 -147 -224 -311
Total Pre-Tax Income 		-41 -46 -100 -155 -147 -224 -311
Total Operating Income		 -42 -46 -101 -161 -166 -262 -349
Total Gross Profit		 2.93 34 73 47 79 47 39
Total Revenue		 2.93 34 73 47 79 47 39
Operating Revenue		 2.93 34 73 47 79 47 39
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 45 80 173 208 244 309 389
Selling, General & Admin Expense		 7.98 18 36 44 55 64 68
Research & Development Expense		 37 62 137 164 189 240 317
Impairment Charge		 - - - 0.00 0.00 4.93 3.86
Total Other Income / (Expense), net		 0.96 0.71 0.31 6.45 19 38 38
Other Income / (Expense), net		 0.96 0.71 0.31 6.45 19 38 38
Basic Earnings per Share		 ($24.28) ($3.15) ($2.09) ($2.87) ($2.52) ($2.98) ($3.69)
Weighted Average Basic Shares Outstanding		 1.70M 17.35M 47.99M 53.93M 58.37M 75.04M 84.49M
Diluted Earnings per Share		 ($24.28) ($3.15) ($2.09) ($2.87) ($2.52) ($2.98) ($3.69)
Weighted Average Diluted Shares Outstanding		 1.70M 17.35M 47.99M 53.93M 58.37M 75.04M 84.49M
Weighted Average Basic & Diluted Shares Outstanding		 1.70M 17.35M 47.99M 55.18M 61.11M 64.94M 81.64M

Quarterly Income Statements for Kymera Therapeutics

This table shows Kymera Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -53 -14 -49 -42 -62 -71 -66 -77 -82 -87 -69
Consolidated Net Income / (Loss)		 -53 -14 -49 -42 -62 -71 -66 -77 -82 -87 -69
Net Income / (Loss) Continuing Operations		 -53 -14 -49 -42 -62 -71 -66 -77 -82 -87 -69
Total Pre-Tax Income 		-53 -14 -49 -42 -62 -71 -66 -77 -82 -87 -69
Total Operating Income		 -58 -19 -58 -51 -72 -81 -74 -85 -93 -98 -84
Total Gross Profit		 4.73 48 10 26 3.74 7.39 22 11 2.76 2.87 34
Total Revenue		 4.73 48 10 26 3.74 7.39 22 11 2.76 2.87 34
Operating Revenue		 4.73 48 10 26 3.74 7.39 22 11 2.76 2.87 34
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 62 67 68 77 76 88 97 96 95 101 119
Selling, General & Admin Expense		 14 14 14 17 15 16 16 18 17 17 20
Research & Development Expense		 48 53 49 59 60 72 80 78 74 84 98
Impairment Charge		 0.00 - 4.93 0.00 0.00 - 0.00 0.00 3.86 - 0.00
Total Other Income / (Expense), net		 4.64 4.94 9.27 8.86 9.64 10 8.85 7.94 10 11 15
Other Income / (Expense), net		 4.64 4.94 9.27 8.86 9.64 10 8.85 7.94 10 11 15
Basic Earnings per Share		 ($0.90) ($0.25) ($0.69) ($0.58) ($0.82) ($0.89) ($0.82) ($0.95) ($0.94) ($0.98) ($0.71)
Weighted Average Basic Shares Outstanding		 58.42M 58.37M 70.77M 73.06M 76.13M 75.04M 80.15M 80.45M 87.30M 84.49M 97.53M
Diluted Earnings per Share		 ($0.90) ($0.25) ($0.69) ($0.58) ($0.82) ($0.89) ($0.82) ($0.95) ($0.94) ($0.98) ($0.71)
Weighted Average Diluted Shares Outstanding		 58.42M 58.37M 70.77M 73.06M 76.13M 75.04M 80.15M 80.45M 87.30M 84.49M 97.53M
Weighted Average Basic & Diluted Shares Outstanding		 55.49M 61.11M 61.36M 61.75M 64.77M 64.94M 65.12M 71.50M 71.95M 81.64M 82.26M

Annual Cash Flow Statements for Kymera Therapeutics

This table details how cash moves in and out of Kymera Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 36 -45 21 20 41 10 237
Net Cash From Operating Activities		 18 88 -129 -153 -103 -195 -233
Net Cash From Continuing Operating Activities		 18 88 -129 -153 -103 -195 -233
Net Income / (Loss) Continuing Operations		 -41 -46 -100 -155 -147 -224 -311
Consolidated Net Income / (Loss)		 -41 -46 -100 -155 -147 -224 -311
Depreciation Expense		 0.83 1.76 2.40 2.98 3.57 7.37 8.31
Non-Cash Adjustments To Reconcile Net Income		 1.64 6.24 32 34 37 49 56
Changes in Operating Assets and Liabilities, net		 57 126 -63 -36 3.91 -27 14
Net Cash From Investing Activities		 -16 -423 -100 21 140 -404 -521
Net Cash From Continuing Investing Activities		 -16 -423 -100 21 140 -404 -521
Purchase of Property, Plant & Equipment		 -0.53 -9.10 -1.60 -2.84 -34 -13 -1.45
Purchase of Investments		 -16 -529 -456 -446 -189 -901 -1,008
Sale and/or Maturity of Investments		 0.00 116 358 469 364 510 488
Net Cash From Financing Activities		 35 289 250 153 4.19 609 991
Net Cash From Continuing Financing Activities		 35 289 250 153 4.19 609 991
Repayment of Debt		 -0.37 -0.55 -0.85 -1.13 -0.08 -1.58 -1.49
Issuance of Debt		 0.00 0.00 241 - 0.00 0.00 656
Issuance of Common Equity		 0.00 183 0.79 153 2.86 12 62
Other Financing Activities, net		 0.07 14 9.98 1.15 1.41 599 274
Cash Interest Paid		 0.05 0.12 0.16 0.18 0.16 0.21 0.31

Quarterly Cash Flow Statements for Kymera Therapeutics

This table details how cash moves in and out of Kymera Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 29 29 -16 -26 43 9.55 -30 246 -223 244 -213
Net Cash From Operating Activities		 -32 8.05 -40 -43 -50 -62 -79 -60 -27 -67 -89
Net Cash From Continuing Operating Activities		 -32 8.05 -40 -43 -50 -62 -79 -60 -27 -67 -89
Net Income / (Loss) Continuing Operations		 -53 -14 -49 -42 -62 -71 -66 -77 -82 -87 -69
Consolidated Net Income / (Loss)		 -53 -14 -49 -42 -62 -71 -66 -77 -82 -87 -69
Depreciation Expense		 0.90 0.89 1.46 1.94 1.99 1.99 2.05 2.08 2.15 2.03 2.02
Non-Cash Adjustments To Reconcile Net Income		 11 9.64 16 10 14 9.02 -7.35 32 19 12 13
Changes in Operating Assets and Liabilities, net		 9.54 12 -8.67 -13 -3.24 -2.04 -8.27 -17 34 5.79 -35
Net Cash From Investing Activities		 61 19 -331 16 -158 69 49 60 -235 -394 -143
Net Cash From Continuing Investing Activities		 61 19 -331 16 -158 69 49 60 -235 -394 -143
Purchase of Property, Plant & Equipment		 -8.08 -12 -7.40 -4.69 0.19 -0.94 -0.47 -0.70 -0.18 -0.11 -0.43
Purchase of Investments		 -29 -46 -423 -104 -296 -78 -84 -58 -368 -498 -276
Sale and/or Maturity of Investments		 98 76 99 124 138 148 133 119 132 104 134
Net Cash From Financing Activities		 -0.21 1.93 354 1.41 251 2.77 0.26 246 40 705 19
Net Cash From Continuing Financing Activities		 -0.21 1.93 354 0.28 252 2.77 0.26 246 40 705 19
Repayment of Debt		 -0.34 0.93 -0.29 -0.35 -0.64 -0.29 -0.28 -0.38 -0.42 -0.42 -0.43
Issuance of Common Equity		 0.13 0.56 305 0.63 252 -546 0.54 245 -233 49 19
Cash Interest Paid		 0.04 0.05 0.05 0.04 0.05 0.06 0.08 0.08 0.08 0.08 0.07

Annual Balance Sheets for Kymera Therapeutics

This table presents Kymera Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 117 487 606 603 576 978 1,743
Total Current Assets		 93 302 451 419 405 510 871
Cash & Equivalents		 76 31 48 68 110 120 357
Short-Term Investments		 16 265 394 339 265 368 491
Accounts Receivable		 0.00 0.58 0.00 0.00 15 - 0.00
Prepaid Expenses		 0.89 4.70 8.72 9.71 12 22 23
Other Current Assets		 0.00 0.86 0.14 2.54 3.76 - 0.00
Plant, Property, & Equipment, net		 3.79 11 12 13 48 50 43
Total Noncurrent Assets		 20 174 143 170 122 417 828
Long-Term Investments		 0.00 163 125 152 61 362 771
Other Noncurrent Operating Assets		 20 11 18 18 61 55 57
Total Liabilities & Shareholders' Equity		 117 487 606 603 576 978 1,743
Total Liabilities		 82 203 146 113 181 142 163
Total Current Liabilities		 35 111 93 71 86 68 83
Accounts Payable		 3.28 4.37 4.01 4.34 7.08 5.99 4.02
Accrued Expenses		 4.57 10 23 28 34 35 42
Current Deferred Revenue		 23 93 62 35 38 14 23
Other Current Liabilities		 3.38 3.37 3.83 4.25 6.87 13 14
Total Noncurrent Liabilities		 47 93 54 42 95 75 80
Noncurrent Deferred Revenue		 30 78 39 28 17 0.00 11
Other Noncurrent Operating Liabilities		 18 15 14 14 78 75 68
Total Equity & Noncontrolling Interests		 -74 284 460 490 395 836 1,580
Total Preferred & Common Equity		 -74 284 460 490 395 836 1,580
Preferred Stock		 0.00 0.00 0.00 - - 0.00 0.00
Total Common Equity		 -74 284 460 490 395 836 1,580
Common Stock		 2.04 413 689 879 926 1,592 2,644
Retained Earnings		 -76 -129 -229 -384 -531 -755 -1,066
Accumulated Other Comprehensive Income / (Loss)		 0.01 -0.13 -0.66 -4.95 -0.55 -1.49 1.80

Quarterly Balance Sheets for Kymera Therapeutics

This table presents Kymera Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 638 614 582 552 868 826 1,035 918 1,131 1,102 1,669
Total Current Assets		 494 412 385 376 537 525 569 501 728 528 677
Cash & Equivalents		 156 50 52 81 94 68 111 90 336 113 144
Short-Term Investments		 326 347 315 277 427 442 439 373 330 393 507
Accounts Receivable		 - - - - 0.00 0.00 0.00 0.00 40 0.00 0.00
Prepaid Expenses		 9.23 11 14 14 15 14 17 18 23 23 27
Other Current Assets		 2.88 3.32 4.12 3.78 2.03 1.70 1.32 20 0.00 0.00 0.00
Plant, Property, & Equipment, net		 13 17 27 36 49 52 51 49 49 45 42
Total Noncurrent Assets		 132 185 169 141 282 249 415 368 354 529 950
Long-Term Investments		 114 119 105 77 224 192 361 312 298 473 895
Other Noncurrent Operating Assets		 18 66 64 64 57 56 54 56 57 56 55
Total Liabilities & Shareholders' Equity		 638 614 582 552 868 826 1,035 918 1,131 1,102 1,669
Total Liabilities		 126 152 147 157 157 141 142 132 160 156 129
Total Current Liabilities		 91 62 55 63 56 62 67 59 88 72 63
Accounts Payable		 6.33 6.48 3.75 4.98 6.81 6.51 6.49 10 5.78 5.51 13
Accrued Expenses		 25 19 22 26 16 24 27 23 28 29 35
Current Deferred Revenue		 56 32 24 27 23 19 20 11 40 23 0.00
Other Current Liabilities		 4.33 4.70 4.07 4.45 11 13 13 14 14 14 15
Total Noncurrent Liabilities		 34 90 92 94 101 79 75 73 72 84 67
Noncurrent Deferred Revenue		 21 25 20 16 24 3.19 0.00 0.00 - 14 0.00
Other Noncurrent Operating Liabilities		 13 65 71 77 77 76 75 73 72 70 67
Total Equity & Noncontrolling Interests		 513 462 435 396 711 685 893 786 971 946 1,540
Total Preferred & Common Equity		 513 462 435 396 711 685 893 786 971 946 1,540
Preferred Stock		 - - - - - - - - 0.00 0.00 0.00
Total Common Equity		 513 462 435 396 711 685 893 786 971 946 1,540
Common Stock		 868 890 903 914 1,292 1,308 1,575 1,606 1,868 1,924 2,679
Retained Earnings		 -349 -425 -464 -516 -579 -621 -684 -820 -897 -979 -1,135
Accumulated Other Comprehensive Income / (Loss)		 -5.91 -3.04 -3.64 -2.45 -1.78 -2.10 1.93 -0.06 0.28 1.50 -4.19

Annual Metrics And Ratios for Kymera Therapeutics

This table displays calculated financial ratios and metrics derived from Kymera Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 1,059.99% 114.00% -35.71% 67.84% -40.11% -16.70%
EBITDA Growth		 0.00% -8.43% -123.18% -55.21% 5.55% -50.97% -39.98%
EBIT Growth		 0.00% -10.54% -119.81% -54.47% 5.07% -52.32% -39.08%
NOPAT Growth		 0.00% -9.71% -117.11% -60.41% -2.65% -58.06% -33.54%
Net Income Growth		 0.00% -10.54% -119.81% -54.47% 5.07% -52.32% -39.08%
EPS Growth		 0.00% 87.03% 33.65% -37.32% 12.20% -18.25% -23.83%
Operating Cash Flow Growth		 0.00% 392.21% -246.31% -18.72% 32.83% -89.16% -19.74%
Free Cash Flow Firm Growth		 0.00% 0.00% -261.19% -10.39% 5.04% -45.41% -5.20%
Invested Capital Growth		 0.00% -205.23% 38.25% 35.77% 40.38% 63.03% -160.21%
Revenue Q/Q Growth		 0.00% 0.00% 3.54% 1.88% 67.77% -46.24% -10.34%
EBITDA Q/Q Growth		 0.00% 0.00% -27.58% -0.47% 12.55% -34.30% -5.64%
EBIT Q/Q Growth		 0.00% 0.00% -27.05% -0.55% 12.24% -33.67% -5.50%
NOPAT Q/Q Growth		 0.00% 0.00% -26.74% -2.96% 10.45% -30.69% -5.16%
Net Income Q/Q Growth		 0.00% 0.00% -26.85% -0.63% 12.24% -33.67% -5.50%
EPS Q/Q Growth		 0.00% 0.00% -116.02% 3.37% 11.89% -27.35% -2.50%
Operating Cash Flow Q/Q Growth		 0.00% -9.51% -16.52% -0.78% 31.63% -56.01% -2.18%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 2.16% 16.76% -29.67% -0.88%
Invested Capital Q/Q Growth		 0.00% 0.00% 15.61% 16.18% -5.26% 15.44% -22.45%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,377.68% -128.78% -134.31% -324.25% -182.46% -459.90% -772.84%
Operating Margin		 -1,438.48% -136.05% -138.03% -344.37% -210.62% -555.82% -891.07%
EBIT Margin		 -1,405.79% -133.96% -137.60% -330.60% -186.99% -475.57% -794.04%
Profit (Net Income) Margin		 -1,405.79% -133.96% -137.60% -330.60% -186.99% -475.57% -794.04%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -118.95% -28.62% -26.96% -32.60% -33.21% -36.38% -25.78%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -35.34% -15.10% -18.34% -25.61% -24.93% -28.81% -22.89%
Return on Assets (ROA)		 -35.34% -15.10% -18.34% -25.61% -24.93% -28.81% -22.89%
Return on Common Equity (ROCE)		 255.26% -18.82% -26.96% -32.60% -33.21% -36.38% -25.78%
Return on Equity Simple (ROE_SIMPLE)		 55.43% -16.06% -21.80% -31.58% -37.21% -26.79% 0.00%
Net Operating Profit after Tax (NOPAT)		 -30 -32 -70 -113 -116 -183 -245
NOPAT Margin		 -1,006.94% -95.24% -96.62% -241.06% -147.43% -389.07% -623.75%
Net Nonoperating Expense Percent (NNEP)		 -12.73% -4.79% -5.82% -7.44% -6.24% -6.33% -5.41%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -23.03% -29.34% -21.92% -15.48%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 272.02% 53.57% 49.90% 93.61% 70.03% 134.97% 173.90%
R&D to Revenue		 1,266.46% 182.48% 188.13% 350.76% 240.59% 510.38% 807.34%
Operating Expenses to Revenue		 1,538.48% 236.05% 238.03% 444.37% 310.62% 655.82% 991.07%
Earnings before Interest and Taxes (EBIT)		 -41 -46 -100 -155 -147 -224 -311
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -40 -44 -98 -152 -143 -216 -303
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 9.71 7.10 2.79 3.58 3.12 3.54
Price to Tangible Book Value (P/TBV)		 0.00 9.71 7.10 2.79 3.58 3.12 3.54
Price to Revenue (P/Rev)		 42.64 80.99 44.80 29.24 17.98 55.35 142.78
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 48.48 67.51 37.00 17.30 12.42 37.27 101.47
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 7.94 26.07 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 26.98 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -2.65 -1.73 -1.38 -1.19 -1.13 -1.05 -1.02
Leverage Ratio		 3.37 1.90 1.47 1.27 1.33 1.26 1.13
Compound Leverage Factor		 3.37 1.90 1.47 1.27 1.33 1.26 1.13
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 314.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -214.59% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.54 8.00 13.14 6.30 3.36 9.73 19.71
Noncontrolling Interest Sharing Ratio		 314.59% 34.24% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 2.69 2.73 4.88 5.88 4.73 7.53 10.47
Quick Ratio		 2.66 2.68 4.78 5.71 4.55 7.21 10.19
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 85 -137 -152 -144 -209 -220
Operating Cash Flow to CapEx		 3,365.60% 968.89% -8,074.26% -5,397.92% -298.22% -1,515.04% -16,072.53%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.03 0.11 0.13 0.08 0.13 0.06 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.77 4.65 6.41 3.71 2.56 0.95 0.84
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -57 -175 -108 -69 -41 -15 -40
Invested Capital Turnover		 -0.05 -0.29 -0.52 -0.53 -1.42 -1.66 -1.42
Increase / (Decrease) in Invested Capital		 0.00 -118 67 39 28 26 -24
Enterprise Value (EV)		 142 2,298 2,695 810 976 1,755 3,979
Market Capitalization		 125 2,756 3,263 1,369 1,413 2,606 5,598
Book Value per Share		 ($43.81) $6.39 $8.94 $8.93 $7.12 $12.90 $21.96
Tangible Book Value per Share		 ($43.81) $6.39 $8.94 $8.93 $7.12 $12.90 $21.96
Total Capital		 35 284 460 490 395 836 1,580
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -92 -459 -568 -559 -436 -851 -1,619
Capital Expenditures (CapEx)		 0.53 9.10 1.60 2.84 34 13 1.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -34 -104 -84 -59 -55 -46 -60
Debt-free Net Working Capital (DFNWC)		 58 192 359 348 320 443 788
Net Working Capital (NWC)		 58 192 359 348 320 443 788
Net Nonoperating Expense (NNE)		 12 13 30 42 31 41 67
Net Nonoperating Obligations (NNO)		 -92 -459 -568 -559 -436 -851 -1,619
Total Depreciation and Amortization (D&A)		 0.83 1.76 2.40 2.98 3.57 7.37 8.31
Debt-free, Cash-free Net Working Capital to Revenue		 -1,147.99% -306.99% -114.90% -126.20% -70.31% -98.24% -153.72%
Debt-free Net Working Capital to Revenue		 1,986.20% 563.32% 492.55% 743.33% 406.69% 940.05% 2,009.65%
Net Working Capital to Revenue		 1,986.20% 563.32% 492.55% 743.33% 406.69% 940.05% 2,009.65%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.15) ($2.09) ($2.87) ($2.52) ($2.98) ($3.69)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 44.81M 51.70M 53.93M 58.37M 75.04M 84.49M
Adjusted Diluted Earnings per Share		 $0.00 ($3.15) ($2.09) ($2.87) ($2.52) ($2.98) ($3.69)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 44.81M 51.70M 53.93M 58.37M 75.04M 84.49M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($3.15) ($2.09) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 17.35M 47.99M 55.18M 61.11M 64.94M 81.64M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -32 -70 -113 -116 -180 -242
Normalized NOPAT Margin		 -1,006.94% -95.24% -96.62% -241.06% -147.43% -381.75% -616.87%
Pre Tax Income Margin		 -1,405.79% -133.96% -137.60% -330.60% -186.99% -475.57% -794.04%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Kymera Therapeutics

This table displays calculated financial ratios and metrics derived from Kymera Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 81,642,394.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 81,642,394.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.85
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -50.50% 196.70% 8.67% 55.33% -20.88% -84.56% 114.83% -55.26% -26.12% -61.17% 55.50%
EBITDA Growth		 -23.05% 60.42% -17.60% -5.87% -16.41% -410.24% -34.90% -85.75% -32.27% -23.54% -5.79%
EBIT Growth		 -22.94% 58.79% -18.64% -8.41% -18.20% -392.43% -35.06% -82.15% -31.51% -22.94% -5.57%
NOPAT Growth		 -28.13% 50.01% -27.59% -17.38% -25.41% -318.16% -28.70% -66.04% -28.28% -21.22% -13.07%
Net Income Growth		 -22.94% 58.79% -18.64% -8.41% -18.20% -392.43% -35.06% -82.15% -31.51% -22.94% -5.57%
EPS Growth		 -13.92% 57.63% 1.43% 13.43% 8.89% -256.00% -18.84% -63.79% -14.63% -10.11% 13.41%
Operating Cash Flow Growth		 7.65% 120.35% 9.96% -21.78% -58.59% -867.98% -99.92% -39.47% 45.99% -8.03% -12.24%
Free Cash Flow Firm Growth		 -9.22% 36.77% 16.25% 29.39% 14.35% -98.93% -59.26% -54.45% 29.75% 46.67% 56.36%
Invested Capital Growth		 52.52% 40.38% 37.41% 52.65% 53.98% 63.03% 131.86% 148.11% -79.69% -160.21% -155.97%
Revenue Q/Q Growth		 -71.37% 912.80% -78.52% 149.34% -85.42% 97.65% 198.89% -48.07% -75.92% 3.87% 1,096.97%
EBITDA Q/Q Growth		 -37.13% 74.07% -249.45% 14.80% -50.78% -13.66% 7.61% -17.31% -7.37% -6.15% 20.88%
EBIT Q/Q Growth		 -36.26% 72.82% -237.95% 13.38% -48.56% -13.23% 7.31% -16.82% -7.26% -5.85% 20.40%
NOPAT Q/Q Growth		 -32.56% 66.42% -199.46% 11.94% -41.63% -11.97% 7.84% -13.61% -9.42% -5.81% 14.04%
Net Income Q/Q Growth		 -36.26% 72.82% -237.95% 13.38% -48.56% -13.23% 7.31% -16.82% -7.26% -5.85% 20.40%
EPS Q/Q Growth		 -34.33% 72.22% -176.00% 15.94% -41.38% -8.54% 7.87% -15.85% 1.05% -4.26% 27.55%
Operating Cash Flow Q/Q Growth		 10.24% 125.42% -592.12% -8.45% -16.89% -23.10% -28.11% 24.34% 54.73% -146.21% -33.10%
Free Cash Flow Firm Q/Q Growth		 -7.31% 50.40% -46.06% 9.17% -30.16% -15.20% -16.94% 11.92% 40.80% 12.55% 4.31%
Invested Capital Q/Q Growth		 -6.43% -5.26% 18.41% 48.20% -3.44% 15.44% 170.32% -21.79% -486.38% -22.45% 84.87%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,099.24% -28.14% -457.82% -156.43% -1,617.21% -930.01% -287.48% -649.44% -2,895.30% -2,958.86% -195.58%
Operating Margin		 -1,216.35% -40.33% -562.18% -198.54% -1,927.93% -1,092.17% -336.77% -736.82% -3,347.36% -3,409.79% -244.88%
EBIT Margin		 -1,118.17% -30.01% -472.02% -163.98% -1,670.33% -956.88% -296.75% -667.60% -2,973.05% -3,029.64% -201.47%
Profit (Net Income) Margin		 -1,118.17% -30.01% -472.02% -163.98% -1,670.33% -956.88% -296.75% -667.60% -2,973.05% -3,029.64% -201.47%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,729.46%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,728.58%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,720.99%
Return on Equity (ROE)		 -36.87% -33.21% -26.35% -28.18% -26.00% -36.38% -32.17% -33.26% -32.09% -25.78% -8.48%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,225.90% -2,904.87% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -87.97% -4.00% -50.58% -20.63% -184.30% -57.98% -19.56% -30.50% -121.69% -87.32% -8.02%
Return on Assets (ROA)		 -87.97% -4.00% -50.58% -20.63% -184.30% -57.98% -19.56% -30.50% -121.69% -87.32% -8.02%
Return on Common Equity (ROCE)		 -36.87% -33.21% -26.35% -28.18% -26.00% -36.38% -32.17% -33.26% -32.09% -25.78% -8.48%
Return on Equity Simple (ROE_SIMPLE)		 -42.34% 0.00% -21.74% -23.05% -18.76% 0.00% -30.64% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -40 -14 -40 -36 -50 -57 -52 -59 -65 -69 -59
NOPAT Margin		 -851.44% -28.23% -393.52% -138.98% -1,349.55% -764.52% -235.74% -515.77% -2,343.15% -2,386.85% -171.42%
Net Nonoperating Expense Percent (NNEP)		 -2.45% -0.17% -1.28% -1.09% -1.78% -2.21% -1.77% -2.09% -1.84% -1.49% -0.89%
Return On Investment Capital (ROIC_SIMPLE)		 - -3.42% - - - -6.76% -6.63% -6.09% -6.84% -4.34% -3.83%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 298.65% 29.71% 139.73% 67.73% 413.12% 220.88% 73.62% 153.76% 627.21% 589.86% 59.24%
R&D to Revenue		 1,017.70% 110.62% 474.57% 230.81% 1,614.81% 971.29% 363.14% 683.06% 2,680.68% 2,919.92% 285.65%
Operating Expenses to Revenue		 1,316.35% 140.33% 662.18% 298.54% 2,027.93% 1,192.17% 436.77% 836.82% 3,447.36% 3,509.79% 344.88%
Earnings before Interest and Taxes (EBIT)		 -53 -14 -49 -42 -62 -71 -66 -77 -82 -87 -69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -52 -13 -47 -40 -61 -69 -64 -75 -80 -85 -67
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.95 3.58 3.14 2.67 3.27 3.12 2.26 2.93 4.28 3.54 4.42
Price to Tangible Book Value (P/TBV)		 1.95 3.58 3.14 2.67 3.27 3.12 2.26 2.93 4.28 3.54 4.42
Price to Revenue (P/Rev)		 16.44 17.98 28.09 20.68 33.38 55.35 30.19 63.56 92.53 142.78 132.10
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 93.23 223.50 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 7.16 12.42 18.71 12.75 22.98 37.27 17.02 42.02 70.15 101.47 102.07
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.13 -1.13 -1.07 -1.05 -1.04 -1.05 -1.02 -1.01 -1.03 -1.02 -1.00
Leverage Ratio		 1.31 1.33 1.26 1.26 1.23 1.26 1.19 1.18 1.16 1.13 1.11
Compound Leverage Factor		 1.31 1.33 1.26 1.26 1.23 1.26 1.19 1.18 1.16 1.13 1.11
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 2.09 4.12 8.16 7.35 11.90 10.25 7.23 10.07 14.63 20.13 30.92
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.95 4.73 9.57 8.45 8.55 7.53 8.49 8.32 7.38 10.47 10.81
Quick Ratio		 5.66 4.55 9.27 8.21 8.27 7.21 7.85 8.06 7.07 10.19 10.39
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -84 -42 -61 -55 -72 -83 -97 -85 -50 -44 -42
Operating Cash Flow to CapEx		 -391.77% 69.20% -534.87% -915.68% 0.00% -6,600.85% -16,948.61% -8,616.40% -14,977.90% -62,968.87% -20,470.05%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.08 0.13 0.11 0.13 0.11 0.06 0.07 0.05 0.04 0.03 0.04
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.92 2.56 2.38 2.24 2.00 0.95 1.20 0.89 0.91 0.84 1.13
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -39 -41 -34 -17 -18 -15 11 8.41 -32 -40 -6.02
Invested Capital Turnover		 -0.77 -1.42 -1.81 -3.26 -3.05 -1.66 -5.12 -9.86 -1.73 -1.42 21.76
Increase / (Decrease) in Invested Capital		 43 28 20 19 21 26 44 26 -14 -24 -17
Enterprise Value (EV)		 335 976 1,486 1,129 2,012 1,755 1,002 1,879 3,068 3,979 5,254
Market Capitalization		 770 1,413 2,231 1,832 2,923 2,606 1,778 2,842 4,047 5,598 6,800
Book Value per Share		 $7.14 $7.12 $10.05 $11.16 $14.46 $12.90 $12.11 $14.92 $13.23 $21.96 $18.86
Tangible Book Value per Share		 $7.14 $7.12 $10.05 $11.16 $14.46 $12.90 $12.11 $14.92 $13.23 $21.96 $18.86
Total Capital		 396 395 711 685 893 836 786 971 946 1,580 1,540
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -435 -436 -745 -702 -911 -851 -775 -963 -979 -1,619 -1,546
Capital Expenditures (CapEx)		 8.08 12 7.40 4.69 -0.19 0.94 0.47 0.70 0.18 0.11 0.43
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -45 -55 -39 -47 -48 -46 -21 -25 -49 -60 -36
Debt-free Net Working Capital (DFNWC)		 313 320 481 463 502 443 442 641 457 788 615
Net Working Capital (NWC)		 313 320 481 463 502 443 442 641 457 788 615
Net Nonoperating Expense (NNE)		 13 0.85 8.08 6.41 12 14 13 17 17 18 10
Net Nonoperating Obligations (NNO)		 -435 -436 -745 -702 -911 -851 -775 -963 -979 -1,619 -1,546
Total Depreciation and Amortization (D&A)		 0.90 0.89 1.46 1.94 1.99 1.99 2.05 2.08 2.15 2.03 2.02
Debt-free, Cash-free Net Working Capital to Revenue		 -96.69% -70.31% -49.65% -52.73% -54.57% -98.24% -35.98% -55.15% -111.95% -153.72% -70.21%
Debt-free Net Working Capital to Revenue		 667.14% 406.69% 605.84% 523.17% 573.51% 940.05% 750.55% 1,433.18% 1,044.32% 2,009.65% 1,194.32%
Net Working Capital to Revenue		 667.14% 406.69% 605.84% 523.17% 573.51% 940.05% 750.55% 1,433.18% 1,044.32% 2,009.65% 1,194.32%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.90) ($0.25) ($0.69) ($0.58) ($0.82) ($0.89) ($0.82) ($0.95) ($0.94) ($0.98) ($0.71)
Adjusted Weighted Average Basic Shares Outstanding		 58.42M 58.37M 70.77M 73.06M 76.13M 75.04M 80.15M 80.45M 87.30M 84.49M 97.53M
Adjusted Diluted Earnings per Share		 ($0.90) ($0.25) ($0.69) ($0.58) ($0.82) ($0.89) ($0.82) ($0.95) ($0.94) ($0.98) ($0.71)
Adjusted Weighted Average Diluted Shares Outstanding		 58.42M 58.37M 70.77M 73.06M 76.13M 75.04M 80.15M 80.45M 87.30M 84.49M 97.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 55.49M 61.11M 61.36M 61.75M 64.77M 64.94M 65.12M 71.50M 71.95M 81.64M 82.26M
Normalized Net Operating Profit after Tax (NOPAT)		 -40 -14 -37 -36 -50 -57 -52 -59 -62 -69 -59
Normalized NOPAT Margin		 -851.44% -28.23% -360.01% -138.98% -1,349.55% -764.52% -235.74% -515.77% -2,245.52% -2,386.85% -171.42%
Pre Tax Income Margin		 -1,118.17% -30.01% -472.02% -163.98% -1,670.33% -956.88% -296.75% -667.60% -2,973.05% -3,029.64% -201.47%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here is a concise, investor-focused snapshot of Kymera Therapeutics (KYMR) using the last four years of quarterly results. It highlights liquidity trends, profitability, and capital deployment across income, balance sheet, and cash flow data.

  • Large net cash from financing activities in Q4 2025: +$705.22 million, driven by equity financing, boosting the company’s liquidity runway.
  • Equity issuance in Q4 2025: +$48.83 million, adding another cash buffer for operations and investing.
  • Net change in cash & equivalents for Q4 2025: +$244.07 million, expanding the cash balance for a period with high investing activity.
  • Liquidity snapshot (as of Q3 2025): Cash & Equivalents $112.95M, Short-Term Investments $392.73M, Total Current Assets $528.30M, Total Assets $1.102B — a solid liquidity cushion relative to liabilities.
  • Financing inflows in 2025 show a rising pattern, culminating in a large Q4 equity raise, indicating continued access to capital markets when needed.
  • Revenue has trended down from 2023 to 2025, with Q4 2025 revenue of $2.87M versus $47.89M in Q4 2023, reflecting pipeline timing and commercialization dynamics.
  • Earnings per share remain negative in recent periods (Q4 2025 basic and diluted EPS of -$0.98), signaling ongoing losses as the company invests in R&D and pipeline development.
  • Net income for Q4 2025 was -$86.98 million, consistent with a multi-quarter loss trend.
  • Net cash from continuing operating activities for Q4 2025 was -$66.75 million, continuing a pattern of negative cash burn from operations.
  • Significant investing outflows in 2025, notably net cash from continuing investing activities of -$394.40 million in Q4 2025 (largely due to large investments purchases), contributing to a heavy cash burn profile.
05/19/26 06:16 PM ETAI Generated. May Contain Errors.

Kymera Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Kymera Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Kymera Therapeutics' net income appears to be on an upward trend, with a most recent value of -$311.35 million in 2025, rising from -$41.25 million in 2019. The previous period was -$223.86 million in 2024. View Kymera Therapeutics' forecast to see where analysts expect Kymera Therapeutics to go next.

Kymera Therapeutics' total operating income in 2025 was -$349.40 million, based on the following breakdown:
  • Total Gross Profit: $39.21 million
  • Total Operating Expenses: $388.61 million

Over the last 6 years, Kymera Therapeutics' total revenue changed from $2.93 million in 2019 to $39.21 million in 2025, a change of 1,236.4%.

Kymera Therapeutics' total liabilities were at $163.15 million at the end of 2025, a 14.6% increase from 2024, and a 98.9% increase since 2019.

In the past 6 years, Kymera Therapeutics' cash and equivalents has ranged from $31.00 million in 2020 to $357.01 million in 2025, and is currently $357.01 million as of their latest financial filing in 2025.

Over the last 6 years, Kymera Therapeutics' book value per share changed from -43.81 in 2019 to 21.96 in 2025, a change of -150.1%.


Related Companies

Financial statements for NASDAQ:KYMR last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel